IRulya Therapeutics Inc. IRLA
29.31 USD -2.36 (-7.45%)
At closeNov 5, 2026, 7:46 PM EST
29.31 0.00 0.00%
After hours · Nov 5, 7:46 PM ET
27.03 Day range 30.91
15.10 52-week range 910.00
- YTD
- -95.63%
- 1 year
- -90.72%
- Market cap
- 29.81M
- EPS (ttm)
- -214.01
- YTD return
- -95.63%
- 1-year return
- -90.72%
- Volume
- 53.74K
- Avg volume
- 44.82K
- Open
- 30.47
- Previous close
- 31.67
- Day's range
- 27.03 – 30.91
- 52-week range
- 15.10 – 910.00
5D -1.36 (-4.43%)
Financials — quick view
IRLA Revenue — quarterly 0
IRLA Net income — quarterly -75.49M
IRLA EPS — quarterly -12.31
News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference 
Quince Therapeutics (NASDAQ: QNCX) renames itself IRulya and sets IRLA ticker 
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease 
Quince Therapeutics Stockholders Approve PIPE, Share Increase and Equity Plans 
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript 
Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript 
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026 
Quince Therapeutics to Participate in September 2026 Investor Conferences 
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Your note
Sign in to keep a note on IRLA — it syncs with the Stock Master app.